Menu Search
Equities

INIFY Laboratories AB

WY60:STU

INIFY Laboratories AB

Actions
  • Price (EUR)0.324
  • Today's Change-0.006 / -1.82%
  • Shares traded0.00
  • 1 Year change-63.35%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

INIFY Laboratories AB is a Sweden-based medical research company that provides cancer diagnostics through laboratory services within pathology. The Company uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The Company origins from ContextVision.

  • Revenue in NOK (TTM)9.57m
  • Net income in NOK-52.64m
  • Incorporated2021
  • Employees26.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.